clinical trial

An Online, Person-Centered, Risk Factor Management Program to Prevent Cognitive Decline: Protocol for A Prospective Behavior-Modification Blinded Endpoint Randomized Controlled Trial

Authors: Yen Ying Lim, Darshini Ayton, Stephanie Perin, Alexandra Lavale, Nawaf Yassi, Rachel Buckley, Christopher Barton, Loren Bruns, Renata Morello, Stephanie Pirotta, Emily Rosenich, Shantha M W Rajaratnam, Richard Sinnott, Amy Brodtmann, Ashley I Bush, Paul Maruff, Leonid Churilov, Anna Barker, Matthew P Pase , BetterBrains Research Group

Journal: Journal of Alzheimer's Disease

Year Published: 2021

Background Several modifiable risk factors for dementia have been identified, although the extent to which their modification leads to improved cognitive outcomes remains unclear. Objective The primary aim is to test the hypothesis that a behavior […]

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

Authors: Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Pei, Tracy McGowan

Journal: Clinical Genitourinary Cancer

Year Published: 2019

Background: The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). Patients and Methods: This was a phase […]

A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder

Authors: G. I. Papakostas, K. Johe, H. Hand, A. Drouillard, P. Russo, G. Kay, R. Kashambwa, B. Hoeppner, M. Flynn, A. Yeung, M. A. Martinson & M. Fava

Journal: Molecular Psychiatry

Year Published: 2019

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and […]

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Authors: Hasegawa T, Hashimoto K, Hashimoto T, Iyo M, Kanahara N, Oda Y, Sasaki T, Shiina A, Yoshida T

Journal: Clinical Psychopharmacology and Neuroscience

Year Published: 2015

OBJECTIVE: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant […]

Back to Publications